Filter posts

Choose Your Own Adventure – The Private Biotech Crossroads

It is a known fact within the private company biopharma universe that the days of …

Indices, IPOs, Approvals - YTD Update Aug 14th, 2012

We are now more than eight months into the year and biotech indices have maintained their outperformance, squeezed …

Only a Few Public Biotechs are Profitable, but There are More of Them Today

Of the 294 biotechs trading on public exchanges today, 248 (84%) focus on drug development. …

Public Exits and Virtual Biotechs - Dreams or Reality?

Here at the 10th Annual BIO Investor Forum, investors and CEOs are debating “all the …

Perspective on Market Valuation for Biotech Drug Developers

Of the 300 publicly traded U.S. biotechs, 219 (73%) are developing drugs. The other 27% …

Nasdaq Biotech Index re-ranking for next Monday

Twice a year, in May and November, the NASDAQ OMX Group re-ranks the closely watched …

IPO Update - April 5th, 2011

The six biotech IPOs of 2011 have followed 2010’s IPO trends; all took significant haircuts getting …

The BTK buyout

Remember this BTK post we wrote back  in February of 2010?  Well, we thought it was time …